Skip to main content
SpringerLink
Log in

Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress

  • Research Paper
  • Published:
Bioprocess and Biosystems Engineering Aims and scope Submit manuscript

Abstract

Biosimilars are highly complex and similar biological drugs are developed with different manufacturing processes which are not similar to originator manufacturing process. Due to this, biosimilar products inherently have quality differences in comparison to innovator molecule which may be related to size, charge and glycosylation. Despite these differences they are supposed to demonstrate similar behaviour in safety and efficacy profile to the reference product and these differences should not be clinically meaningful. Charge variants are one of the critical quality attributes and sources of heterogeneity. In this study, highly purified charge variants cluster (acidic, main peak and basic) of biosimilar product of Xolair were assessed for their impact on in vitro potency and stability at different thermal stress conditions (2–8 °C and − 20 °C). The study data indicating purified charge variants (> 90%) have no impact on in vitro potency and are stable at different thermal stress conditions up to a week.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Xiao Z, Yin X, Han L, Sun B, Shen Z, Liu W, Yu F (2018) Comprehensive approach for evaluating charge heterogeneity in biosimilars. Eur J Pharm Sci 115:19–24. https://doi.org/10.1016/j.ejps.2018.01.016

    Article  CAS  PubMed  Google Scholar 

  2. FDA Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product (2015). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product. Accessed Apr 2015

  3. EMA Guideline on similar biological medicinal products (2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed Oct 2014

  4. Yamaguchi T, Arato T (2011) Quality, safety and efficacy of follow-on biologics in Japan. Biologicals 39:328–332. https://doi.org/10.1016/j.biologicals.2011.06.015

    Article  PubMed  Google Scholar 

  5. Declerck P, Danesi R, Petersel D, Jacobs I (2017) The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs 77:671–677. https://doi.org/10.1007/s40265-017-0717-1

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ishii-Watabe A, Kuwabara T (2019) Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet 34:64–70. https://doi.org/10.1016/j.dmpk.2018.11.004

    Article  CAS  PubMed  Google Scholar 

  7. Hintersteiner B, Lingg N, Janzek E, Mutschlechner O, Loibner H, Jungbauer A (2016) Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein. Biotechnol J 11:1617–1627. https://doi.org/10.1002/biot.201600504

    Article  CAS  PubMed  Google Scholar 

  8. Farjami A, Siahi-Shadbad M, Akbarzadehlaleh P, Roshanzamir K, Molavi O (2019) Evaluation of the physicochemical and biological stability of cetuximab under various stress condition. J Pharm Pharm Sci 22:171–190. https://doi.org/10.18433/jpps30427

    Article  CAS  PubMed  Google Scholar 

  9. Yanchao W, Chen Z, Chao Z, Qiang F, Baohong Z, Yanling B, Nianmin Q, Jianwei Z (2022) Characterization and pre-clinical assessment of a proposed biosimilar to its originator Omalizumab. Eur J Pharm Sci 178:0928–0987. https://doi.org/10.1016/j.ejps.2022.106292

    Article  CAS  Google Scholar 

  10. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YMC (2010) Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 28:509–516. https://doi.org/10.1016/j.tibtech.2010.07.001

    Article  CAS  PubMed  Google Scholar 

  11. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL (2002) Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2 and -3 antibodies modified with biotin. Cancer Biother Radiopharm 17:359–370. https://doi.org/10.1089/108497802760363150

    Article  CAS  PubMed  Google Scholar 

  12. Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129–188. https://doi.org/10.1016/s0378-5173(99)00152-0

    Article  CAS  PubMed  Google Scholar 

  13. Paul M, Vieillard V, Jaccoulet E, Astier A (2012) Long-term stability of diluted solutions of the monoclonal antibody rituximab. Int J Pharm 436:282–290. https://doi.org/10.1016/j.ijpharm.2012.06.063

    Article  CAS  PubMed  Google Scholar 

  14. Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V (2020) Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci 109:169–190. https://doi.org/10.1016/j.xphs.2019.08.009

    Article  CAS  PubMed  Google Scholar 

  15. Zhao YY, Wang N, Liu WH, Tao WJ, Liu LL, Shen ZD (2016) Charge variants of an avastin biosimilar isolation, characterization, in vitro properties and pharmacokinetics in rat. PLoS ONE 17:e0151874. https://doi.org/10.1371/journal.pone.0151874

    Article  CAS  Google Scholar 

  16. Gupta T, Seshadri S (2023) Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods. Ann Pharm Fr (Accepted manuscript). https://doi.org/10.1016/j.pharma.2023.09.003

    Article  Google Scholar 

  17. Gupta T, Kumar A, Seshadri S (2023) Bioprocess challenges in purification of therapeutic protein charge variants. Biotechnol Bioprocess Eng (Accepted manuscript). https://doi.org/10.1007/s12257-023-0078-4

    Article  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Kashiv BioSciences Pvt. Ltd. for support with the necessary facilities and guidance for the completion of the research article.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Institute of Science, Nirma University, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat, India

    Tarun Gupta & Sriram Seshadri

  2. Downstream Process Development, Kashiv BioSciences Pvt Ltd, Ahmedabad, Gujarat, India

    Tarun Gupta

Authors
  1. Tarun Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sriram Seshadri
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Tarun Gupta and Sriram Seshadri performed the literature search. Tarun Gupta contributed to research work related to experiments and data compilation. Sriram Seshadri designed and supervised the research work.

Corresponding author

Correspondence to Sriram Seshadri.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, T., Seshadri, S. Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress. Bioprocess Biosyst Eng 47, 57–64 (2024). https://doi.org/10.1007/s00449-023-02944-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00449-023-02944-8

Keywords

Search

Navigation